<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336317">
  <stage>Registered</stage>
  <submitdate>7/12/2010</submitdate>
  <approvaldate>8/12/2010</approvaldate>
  <actrnumber>ACTRN12610001082099</actrnumber>
  <trial_identification>
    <studytitle>Can olive leaf extract reduce the risk of metabolic disease?</studytitle>
    <scientifictitle>Can olive leaf extract improve insulin sensitivity in middle aged males? A randomized cross-over trial of olive leaf extract in males aged 35 -55, with a body mass index of 25 - 30.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Insulin sensitivity</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Olive leaf extract (Oleuropein) 66mg (15mL), oral once daily for 12 weeks. Crossed over to placebo with a 6 week washout between interventions. There will be no lead in period.</interventions>
    <comparator>placebo control. The placebo is capsulated safflower oil provided once daily for 12 weeks orally.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Insulin sensitivity. THis will be measured by the Matsuda methodl which is best model compared to the euglycaemic clamp. This involved overnight fasting, with an oral glucose tolerance test. Equipment used will be IV cannulation, and syringes. The Liggins Institute has an in-house assay for insulin level.s</outcome>
      <timepoint>Baseline
End of Intervention one (placebo or oleuropein depending in randomization)
End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition (DEXA)</outcome>
      <timepoint>Baseline
End of Intervention one (placebo or oleuropein depending in randomization)
End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>24 hour blood pressure monitoring</outcome>
      <timepoint>Baseline
End of Intervention one (placebo or oleuropein depending in randomization)
End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Wellness questionairre</outcome>
      <timepoint>Baseline
End of Intervention one (placebo or oleuropein depending in randomization)
End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hand grip strength
  Measured with a Jamar dynamometer.</outcome>
      <timepoint>Baseline
End of Intervention one (placebo or oleuropein depending in randomization)
End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resting Energy Expenditure was determined by indirect calirometry using a TrueOne 2400 Metabolic Measurement system (Parvo Medics Inc., Yorba Sandy, Utah).</outcome>
      <timepoint>Baseline
End of Intervention one (placebo or oleuropein depending in randomization)
End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Carotid Intima Thickness measurement - measured by ultrasound</outcome>
      <timepoint>Baseline End of Intervention one (placebo or oleuropein depending in randomization) End of intervention two. (placebo or oleuropein depending in randomization)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood sample for lipid profile: LDL, HDL and total cholesterol</outcome>
      <timepoint>Baseline End of Intervention one (placebo or oleuropein depending in randomization) End of intervention two. (placebo or oleuropein depending in randomization).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood sample for liver function tests: AST, ALT, ALP, GGT</outcome>
      <timepoint>Baseline End of Intervention one (placebo or oleuropein depending in randomization) End of intervention two. (placebo or oleuropein depending in randomization).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood sample for Cytokines that influence insulin sensitivity: Interleukin 6 (IL-6), IL-8, tumour necrosis factor alpha, ultrasensitive CRP, Insulin like growth facotr binding protein 1 (IGBBP1), IGFBP2, IGFBP3</outcome>
      <timepoint>Baseline End of Intervention one (placebo or oleuropein depending in randomization) End of intervention two. (placebo or oleuropein depending in randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood sample for Oxidised LDL</outcome>
      <timepoint>Baseline End of Intervention one (placebo or oleuropein depending in randomization) End of intervention two. (placebo or oleuropein depending in randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Males aged 35 to 55.
BMI 25 - 30</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any medications
BMI outside inclusion range
Smokers
Diabetes
Cardiovascular disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomization by computer
Blinding by coding, key to code kept by Olive leaf extract supplier (Comvita)</concealment>
    <sequence>Computer generation - random number allocation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland / Liggins Institute</primarysponsorname>
    <primarysponsoraddress>2 -  6 Park Ave
Grafton
Auckland 1010</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Comvita</fundingname>
      <fundingaddress>Comvita New Zealand Ltd
23 Wilson Road South
Paengaroa
Te Puke
Bay of Plenty 3189</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to formally assess the impact of olive leaf extract on insulin sensitivity. It will be given as a supplement, without altering other aspects of diet or lifestyle.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Regional Y eithics committee</ethicname>
      <ethicaddress>354 Victoria Street, PO BOX 1031, Hamilton, 3204</ethicaddress>
      <ethicapprovaldate>6/11/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/02/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin de Bock</name>
      <address>Liggins Institute
2-6 Park Avenue
Grafton
Auckland 1010</address>
      <phone>0064992382769</phone>
      <fax />
      <email>m.debock@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Martin de Bock</name>
      <address>Liggins Institute
2-6 Park Avenue
Grafton
Auckland 1010</address>
      <phone>0064992382769</phone>
      <fax />
      <email>m.debock@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Martin de Bock</name>
      <address>Liggins Institute
2-6 Park Avenue
Grafton
Auckland 1010</address>
      <phone />
      <fax />
      <email />
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>